

## Breviscapine

Cat. No.:	HY-107802
CAS No.:	116122-36-2
Molecular Formula:	C <sub>54</sub> H <sub>84</sub> N <sub>16</sub> O <sub>21</sub>
Molecular Weight:	1293.34
Target:	Others
Pathway:	Others
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

# Breviscapine

### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (77.32 mM; ultrasonic and warming and heat to 60°C)  
 H<sub>2</sub>O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

Preparing Stock Solutions	Solvent	1 mg	5 mg	10 mg
	Concentration			
	1 mM	0.7732 mL	3.8660 mL	7.7319 mL
	5 mM	0.1546 mL	0.7732 mL	1.5464 mL
	10 mM	0.0773 mL	0.3866 mL	0.7732 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Breviscapine is a crude flavonoid extract of Breviscapine, which is more than 85% of the active ingredient, Breviscapine. Breviscapine has a wide range of cardiovascular pharmacological activities, such as increasing blood flow, improving microcirculation, dilating blood vessels, reducing blood viscosity, promoting fibrinolysis, inhibiting platelet aggregation and thrombosis. Breviscapine has been used in the study of cerebral infarction and its sequelae, cerebral thrombosis, coronary heart disease and angina pectoris<sup>[1][2]</sup>.

### REFERENCES

- [1]. Gao J, et al. Therapeutic Effects of Breviscapine in Cardiovascular Diseases: A Review. *Front Pharmacol.* 2017 May 23;8:289.  
 [2]. Wen L, et al. Breviscapine: A Review on its Phytochemistry, Pharmacokinetics and Therapeutic Effects. *Am J Chin Med.* 2021;49(6):1369-1397.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA